A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of NPT189 in Healthy Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 24 Dec 2018
At a glance
- Drugs NPT-189 (Primary)
- Indications Amyloidosis
- Focus Adverse reactions
- Sponsors Proclara Biosciences
- 13 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 02 Aug 2018 New trial record
- 26 Jul 2018 According to Proclara Biosciences media release, First Subject Dosed in this study.